Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model

Ann Thorac Surg. 2001 May;71(5):1603-8. doi: 10.1016/s0003-4975(01)02466-3.


Background: A new coating material, poly-2-methoxyethyl acrylate (PMEA), was developed to improve the biocompatibility of cardiopulmonary bypass (CPB) circuits.

Methods: To investigate the efficacy of the PMEA coating for CPB circuits, we compared PMEA-coated circuits (group P, n = 6) with uncoated circuits (group C, n = 6) and heparin (covalent-bonded heparin, Hepaface)-coated circuits (group H, n = 6) in a porcine CPB model.

Results: Platelet counts were significantly preserved in groups P and H compared with those in group C (P versus C, p < 0.05). The plasma levels of thrombin-antithrombin complex and bradykinin were significantly lower at 120 minutes in groups P and H than in group C (thrombin-antithrombin: P versus C, p < 0.05; bradykinin: P versus C, p < 0.05). The amount of fibrinogen adsorbed onto the hollow fibers was markedly less in group P than in groups C and H.

Conclusions: The PMEA coating was equal to heparin coating in preventing reactions induced by CPB circuits, and might be superior to heparin coating in suppressing the adsorption of plasma proteins such as fibrinogen. Thus, PMEA coating may be a suitable means for improving the biocompatibility of CPB circuits.

Publication types

  • Comparative Study

MeSH terms

  • Acrylates*
  • Animals
  • Antithrombin III
  • Bradykinin / blood
  • Cardiopulmonary Bypass / instrumentation*
  • Coated Materials, Biocompatible*
  • Female
  • Fibrinogen / metabolism
  • Heparin
  • Materials Testing
  • Peptide Hydrolases / blood
  • Polymers*
  • Swine


  • Acrylates
  • Coated Materials, Biocompatible
  • Polymers
  • antithrombin III-protease complex
  • poly(2-methoxyethylacrylate)
  • Antithrombin III
  • Fibrinogen
  • Heparin
  • Peptide Hydrolases
  • Bradykinin